Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE (GSK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

GlaxoSmithKline: European Commission Authorizes Nimenix

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/27/2012 | 02:24pm CET

GlaxoSmithKline PLC (>> GlaxoSmithKline plc), the drug company, said Friday that the European Commission has granted marketing authorization for Nimenrix, Meningococcal group A, C, W-135 and Y conjugate vaccine, for active immunization against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135 and Y.

-Shares at 1207 GMT, up a penny, or 0.04%, at 1,420.5 pence valuing the company at GBP71.61 billion.

-By Rory Gallivan, Dow Jones Newswires; 44-20-7842-9411; [email protected]

Stocks mentioned in the article : GlaxoSmithKline plc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
02/16GLAXOSMITHKLINE : GSK submits landmark IMPACT data to European Medicines Agency ..
AQ
02/15GLAXOSMITHKLINE : Details Findings in Organic Research [High-Throughput Automate..
AQ
02/15GLAXOSMITHKLINE : An Application for the Trademark "ELEBRATO" Has Been Filed by ..
AQ
02/15FINDINGS FROM GLAXOSMITHKLINE PLC IN : Efficacy,...
AQ
02/15GLAXOSMITHKLINE : Reports from GlaxoSmithKline plc Provide New Insights into Bio..
AQ
02/15GLAXOSMITHKLINE : Investigators at GlaxoSmithKline plc Release New Data on Monoc..
AQ
02/15GLAXOSMITHKLINE : New Whooping Cough Study Results from GlaxoSmithKline plc Desc..
AQ
02/15GLAXOSMITHKLINE : GSK receives European approval for expanded indication for Flu..
PU
02/14GLOBAL EYE CANCER MARKET REPORT WITH : Global Eye Cancer Market - Global Industr..
AQ
02/14GLAXOSMITHKLINE : GSK submits landmark IMPACT data - Trelegy Ellipta
PU
More news
News from SeekingAlpha
02/16WALL STREET BREAKFAST : Major Recovery For Wall Street 
02/16'Intense' flu season to continue 
02/15YOUR DAILY PHARMA SCOOP : Achaogen Update, Catabasis' Positive Results, Bristol-.. 
02/15Expanded use for Glaxo's flu vaccine Fluarix Tetra OK'd in Europe 
02/15Lanny's January Dividend Income Summary 
Financials ( GBP)
Sales 2018 30 305 M
EBIT 2018 8 227 M
Net income 2018 4 129 M
Debt 2018 13 333 M
Yield 2018 6,07%
P/E ratio 2018 15,09
P/E ratio 2019 13,75
EV / Sales 2018 2,60x
EV / Sales 2019 2,52x
Capitalization 65 379 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 30
Average target price 15,3  GBP
Spread / Average Target 16%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Patrick J. T. Vallance Executive Director, President-R&D
Karenann K. Terrell Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE-1.67%91 131
JOHNSON & JOHNSON-7.19%352 552
NOVARTIS-3.37%224 301
PFIZER-2.84%212 857
ROCHE HOLDING LTD.-9.37%210 327
MERCK AND COMPANY-0.50%149 572